Aronex, Genzyme Corp. General Division deal

The companies amended their 1993 agreement for development of Atragen to treat acute promyelocytic leukemia (APL) and

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE